Esperanza Lázaro Valero

Esperanza lazaro

Esperanza Lázaro Valero (born in Madrid, Spain 1960) is the Country Manager of ev3, an American multinational of breakthrough healthcare technology.

Biography

Esperanza has a University degree in Geography and Modern History by Complutense University of Madrid, where she also studied Art History. Later she completed her studies with a MBA at ICADE. She has a First Level Basketball Trainer title by the Basketball Federation of Madrid. Esperanza is using this knowledge in her management model. She is an expert in Business Management (IESE), leadership and coaching (Instituto de Empresa) and in Advanced Skills in Negotiation (Institute for International Research).

Esperanza Lázaro has been involved with the healthcare industry since 1985, mainly in management positions. She worked in Bayer Laboratories in the diagnosis area and in clinical studies about hematology, biochemistry and diabetes. She collaborated in the launching of the FVIII Recombinante in Baxter Biopharma which was a turning point in treatment of hemophilia.

Esperanza holds the position of Chief Executive with ev3 in Spain and Portugal since 2006. Also from 2011 onwards she is holding the same position in ev3 Technologies Ibérica, S.L, a company specialized in endovascular treatment.

Through ev3, the sixth company in the world in the 2010 ranking of innovative companies, Lázaro is offering a specialized scholarship for Spanish doctors every year to study abroad.